 |
|
|
| |
Tobevibart (VIR-3434), a Monoclonal Antibody, Resistance Analysis in Participants With Chronic HBV: Results From a Phase 1, Single-dose Study
|
| |
| |
European Association for the Study of the Liver (EASL™) Congress; 5-8 June 2024; Milan, Italy.
Hasan Imam,1 Julia di Iulio,1 Thanh Quach,1 Yi-Pei Chen,1 Carley E. McAlister,1 Sonia Maciejewski,1 Keith Boundy,1 Andre Arizpe,1 Kosh Agarwal,2 Man-Fung Yuen,3 Andrea Cathcart,1 Gregory Camus1
1Vir Biotechnology, Inc, San Francisco, CA, USA; 2King's College Hospital, London, UK; 3Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, Hong Kong.
|
| |
|
|
|
|
|
